Current status of superparamagnetic iron oxide contrast agents for liver magnetic resonance imaging
Other outputs

Times Cited
Web of Science99WOS source URL (as at 19/01/2021) Click here for the latest count
Altmetrics Information

Other information
AbstractFive types of superparamagnetic iron oxide (SPIO), i.e. Ferumoxides (Feridex (R) IV, Berlex Laboratories), Ferucarbotran (Resovist (R), Bayer Healthcare), Ferumoxtran-10 (AMI-227 or Code-7227, Combidex (R), AMAG Pharma; Sinerem (R), Guerbet), NC100150 (Clariscan (R), Nycomed,) and (VSOP C184, Ferropharm) have been designed and clinically tested as magnetic resonance contrast agents. However, until now Resovist (R) is current available in only a few countries. The other four agents have been stopped for further development or withdrawn from the market. Another SPIO agent Ferumoxytol (Feraheme (R)) is approved for the treatment of iron deficiency in adult chronic kidney disease patients. Ferumoxytol is comprised of iron oxide particles surrounded by a carbohydrate coat, and it is being explored as a potential imaging approach for evaluating lymph nodes and certain liver tumors.
All Author(s) ListWang YXJ
Journal nameWorld Journal of Gastroenterology
Volume Number21
Issue Number47
LanguagesEnglish-United Kingdom
KeywordsEovist; Gd-EOB-DTPA; hepatocellular carcinoma; liver; magnetic resonance imaging; Primovist; Resovist; Superparamagnetic iron oxide
Web of Science Subject CategoriesGastroenterology & Hepatology

Last updated on 2021-20-01 at 01:35